oxidopamine has been researched along with Cognition Disorders in 23 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients suffering from Parkinson's disease (PD) display cognitive and neuropsychiatric dysfunctions, especially with disease progression." | 1.43 | Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease. ( Dunnett, SB; Kelly, CM; Lelos, MJ; Morgan, RJ; Rosser, AE; Torres, EM, 2016) |
| "Parkinson's disease and Alzheimer's disease (AD) are recognized to coexist on a spectrum of neurodegeneration, and it has been proposed that molecular interactions among pathogenic proteins are a basis for the overlap between these two diseases." | 1.42 | Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer's disease. ( Cudaback, E; Darvas, M; Jorstad, NL; Keene, CD; Melief, EJ; Montine, KS; Montine, TJ; Postupna, N; Sherfield, E; Wilson, A, 2015) |
| "Although the cardinal features of Parkinson's disease (PD) are motor symptoms, PD also causes cognitive deficits including cognitive flexibility and working memory, which are strongly associated with prefrontal cortex (PFC) functions." | 1.40 | Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson's disease. ( Darvas, M; Henschen, CW; Palmiter, RD, 2014) |
| " MRZ-8676 (6,6-dimethyl-2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one) is a novel proprietary, selective, orally bioavailable mGluR5 NAM." | 1.37 | Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia. ( Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M, 2011) |
| "In addition to classic motor symptoms, Parkinson's disease (PD) is characterized by cognitive and emotional deficits, which have been demonstrated to precede motor impairments." | 1.35 | Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. ( Cargnin-Ferreira, E; Da Cunha, C; Dombrowski, PA; Figueiredo, CP; Tadaiesky, MT; Takahashi, RN, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 19 (82.61) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hadadianpour, Z | 1 |
| Fatehi, F | 1 |
| Ayoobi, F | 1 |
| Kaeidi, A | 1 |
| Shamsizadeh, A | 1 |
| Fatemi, I | 1 |
| Grospe, GM | 1 |
| Baker, PM | 1 |
| Ragozzino, ME | 1 |
| Bonito-Oliva, A | 1 |
| Pignatelli, M | 1 |
| Spigolon, G | 1 |
| Yoshitake, T | 1 |
| Seiler, S | 1 |
| Longo, F | 1 |
| Piccinin, S | 1 |
| Kehr, J | 1 |
| Mercuri, NB | 1 |
| Nisticò, R | 1 |
| Fisone, G | 1 |
| Kadowaki Horita, T | 1 |
| Kobayashi, M | 1 |
| Mori, A | 1 |
| Jenner, P | 1 |
| Kanda, T | 1 |
| Darvas, M | 2 |
| Henschen, CW | 1 |
| Palmiter, RD | 1 |
| Ma, Y | 1 |
| Zhan, M | 1 |
| OuYang, L | 1 |
| Li, Y | 1 |
| Chen, S | 1 |
| Wu, J | 1 |
| Chen, J | 1 |
| Luo, C | 1 |
| Lei, W | 1 |
| Lindgren, HS | 1 |
| Klein, A | 1 |
| Dunnett, SB | 3 |
| Croxson, PL | 1 |
| Walton, ME | 1 |
| Boorman, ED | 1 |
| Rushworth, MF | 1 |
| Bannerman, DM | 1 |
| Melief, EJ | 1 |
| Cudaback, E | 1 |
| Jorstad, NL | 1 |
| Sherfield, E | 1 |
| Postupna, N | 1 |
| Wilson, A | 1 |
| Montine, KS | 1 |
| Keene, CD | 1 |
| Montine, TJ | 1 |
| Delaville, C | 1 |
| McCoy, AJ | 1 |
| Gerber, CM | 1 |
| Cruz, AV | 1 |
| Walters, JR | 1 |
| Petri, D | 1 |
| de Souza Silva, MA | 1 |
| Chao, OY | 1 |
| Schnitzler, A | 1 |
| Huston, JP | 1 |
| Tamburrino, A | 1 |
| Churchill, MJ | 1 |
| Wan, OW | 1 |
| Colino-Sanguino, Y | 1 |
| Ippolito, R | 1 |
| Bergstrand, S | 1 |
| Wolf, DA | 1 |
| Herz, NJ | 1 |
| Sconce, MD | 1 |
| Björklund, A | 1 |
| Meshul, CK | 1 |
| Decressac, M | 1 |
| Kwak, C | 1 |
| Lim, CS | 1 |
| Kaang, BK | 1 |
| Lelos, MJ | 1 |
| Morgan, RJ | 1 |
| Kelly, CM | 1 |
| Torres, EM | 1 |
| Rosser, AE | 1 |
| Nezhadi, A | 1 |
| Sheibani, V | 1 |
| Esmaeilpour, K | 1 |
| Shabani, M | 1 |
| Esmaeili-Mahani, S | 1 |
| Tadaiesky, MT | 1 |
| Dombrowski, PA | 1 |
| Figueiredo, CP | 1 |
| Cargnin-Ferreira, E | 1 |
| Da Cunha, C | 1 |
| Takahashi, RN | 1 |
| Pérez, V | 1 |
| Marin, C | 1 |
| Rubio, A | 1 |
| Aguilar, E | 1 |
| Barbanoj, M | 1 |
| Kulisevsky, J | 1 |
| Li, XH | 1 |
| Wang, JY | 1 |
| Gao, G | 1 |
| Chang, JY | 1 |
| Woodward, DJ | 1 |
| Luo, F | 1 |
| Lelos, M | 1 |
| Dekundy, A | 1 |
| Gravius, A | 1 |
| Hechenberger, M | 1 |
| Pietraszek, M | 1 |
| Nagel, J | 1 |
| Tober, C | 1 |
| van der Elst, M | 1 |
| Mela, F | 1 |
| Parsons, CG | 1 |
| Danysz, W | 1 |
| Ramos-Moreno, T | 1 |
| Castillo, CG | 1 |
| Martínez-Serrano, A | 1 |
| Wang, Q | 1 |
| Wang, PH | 1 |
| McLachlan, C | 1 |
| Wong, PT | 1 |
| De Leonibus, E | 1 |
| Pascucci, T | 1 |
| Lopez, S | 1 |
| Oliverio, A | 1 |
| Amalric, M | 1 |
| Mele, A | 1 |
1 review available for oxidopamine and Cognition Disorders
| Article | Year |
|---|---|
Behavioral analysis of motor and non-motor symptoms in rodent models of Parkinson's disease.
Topics: Animals; Cognition Disorders; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; Learning; M | 2010 |
22 other studies available for oxidopamine and Cognition Disorders
| Article | Year |
|---|---|
The effect of orexin-A on motor and cognitive functions in a rat model of Parkinson's disease.
Topics: Animals; Avoidance Learning; Cognition Disorders; Disease Models, Animal; Male; Microinjections; Mot | 2017 |
Cognitive Flexibility Deficits Following 6-OHDA Lesions of the Rat Dorsomedial Striatum.
Topics: Animals; Cognition Disorders; Corpus Striatum; Discrimination, Psychological; Executive Function; Ma | 2018 |
Cognitive impairment and dentate gyrus synaptic dysfunction in experimental parkinsonism.
Topics: Animals; CA1 Region, Hippocampal; Cognition Disorders; Corpus Striatum; Dentate Gyrus; Long-Term Pot | 2014 |
Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex.
Topics: Adenosine A2 Receptor Antagonists; Animals; Cognition; Cognition Disorders; Disease Models, Animal; | 2013 |
Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson's disease.
Topics: Animals; Cognition Disorders; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neuron | 2014 |
The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Choline O-Acetyltransferase; Cognition Disorders; Corpus St | 2014 |
Nigral 6-hydroxydopamine lesion impairs performance in a lateralised choice reaction time task--impact of training and task parameters.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Choice Behavior; Cognition Disorders; | 2014 |
Unilateral medial frontal cortex lesions cause a cognitive decision-making deficit in rats.
Topics: Animals; Cognition Disorders; Decision Making; Dopamine; Frontal Lobe; Functional Laterality; Male; | 2014 |
Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer's disease.
Topics: Adrenergic Agents; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysi | 2015 |
Subthalamic nucleus activity in the awake hemiparkinsonian rat: relationships with motor and cognitive networks.
Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Benzazepines; Cognition Disorde | 2015 |
Serotonergic interaction between medial prefrontal cortex and mesotelencephalic DA system underlies cognitive and affective deficits in hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Cognition Disorders; Disease Models, Animal; Excitatory Amino Acid Agoni | 2015 |
Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Cell Transplantation; Cells, Cultured; Cognition Disorders; Cyclosporine; | 2015 |
Assessments of cognitive abilities in a mouse model of Parkinson's disease with a touch screen test.
Topics: Animals; Cognition; Cognition Disorders; Computers; Conditioning, Operant; Discrimination, Psycholog | 2016 |
Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease.
Topics: Animals; Calbindins; Cognition Disorders; Disease Models, Animal; Dopaminergic Neurons; Female; Fetu | 2016 |
Neurosteroid allopregnanolone attenuates cognitive dysfunctions in 6-OHDA-induced rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Cognition Disorders; Disease Models, Animal; Escap | 2016 |
Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease.
Topics: Adrenergic Agents; Affective Symptoms; Analysis of Variance; Animals; Behavior, Animal; Brain; Brain | 2008 |
Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.
Topics: Animals; Benzylamines; Cognition Disorders; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Mal | 2009 |
High-frequency stimulation of the subthalamic nucleus restores neural and behavioral functions during reaction time task in a rat model of Parkinson's disease.
Topics: Animals; Cognition Disorders; Deep Brain Stimulation; Disease Models, Animal; Electric Stimulation T | 2010 |
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition D | 2011 |
Long term behavioral effects of functional dopaminergic neurons generated from human neural stem cells in the rat 6-OH-DA Parkinson's disease model. Effects of the forced expression of BCL-X(L).
Topics: Animals; bcl-X Protein; Behavior, Animal; Cell Line; Cell Survival; Cells, Cultured; Central Nervous | 2012 |
Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Down-Regulation; Hydroxymethylglutaryl-CoA Red | 2005 |
Spatial deficits in a mouse model of Parkinson disease.
Topics: Analysis of Variance; Animals; Animals, Outbred Strains; Avoidance Learning; Behavior, Animal; Cogni | 2007 |